New Age Thinking: US FDA’s Temple Sees Third Era Of Drug Development
Robert Temple, the FDA's voice of institutional memory, believes drug regulation has quietly entered a third era: the “Age of Individualization.” Unlike the prior eras of safety and efficacy, there is no milestone legislation to set the ground rules.
You may also be interested in...
There are "tremendous concerns" about potential abuse of biomarkers to diagnose pain, Stanford University researcher tells FDA Science Forum.
Roche's Richard Peck says adoption of outcomes-based pricing in the US could be powerful incentive to study precision dosing, although he also calls on drugmakers to put out scientific examples.
CDER's Robert Temple said the US FDA has generally been nervous about using PK/PD analyses to support labeling changes, but that it might be time to rethink the subject.